In basic research, nintedanib in combination with anti-PD-L1 was found to be effective in enhancing the efficacy of immunotherapy, inhibiting tumor growth and metastasis, and reducing pulmonary complications in transplantation tumor models (115). The gene discussed is CD274; the disease is neoplasm.